Gwenn Hansen, Chief Scientific Officer at Nurix Therapeutics, Inc. (NRIX), sold 1,452 shares at $25.47 ($37K) on 2026-09-01, disclosed to the SEC on 2026-09-01.
Scheduled sale ($37k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| NRIX | SELL | 2026-07-30 | $90K | — | Filing → |
| NRIX | SELL | 2026-06-25 | $108K | — | Filing → |
| NRIX | SELL | 2026-04-30 | $53K | — | Filing → |